Myovant Sciences Ltd (MYOV)

[stockguard]

Analyst at Cowen & Co. Reaffirmed Myovant Sciences (MYOV)Stock Rating as a ‘Buy’
Posted by Carillo Anthony on November 2, 2019 at 3:10 pm
Myovant Sciences (MYOV) Rating Reaffirmed
In an analyst note sent to investors on Thursday morning, Cowen & Co. maintained their Buy rating on Myovant Sciences (MYOV) shares.

The stock increased 1.65% or $0.09 during the last trading session, reaching $5.55. About 490,299 shares traded. Myovant Sciences Ltd. (MYOV) has declined 63.47% since November 2, 2018 and is downtrending. It has underperformed by 63.47% the S&P500.

Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on November, 14. They expect $-0.80 EPS, up 19.19 % or $0.19 from last year’s $-0.99 per share. After $-0.89 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts -10.11 % EPS growth.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $497.41 million. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: Finance.Yahoo.com which released: “How Much Are Myovant Sciences Ltd. (NYSE:MYOV) Insiders Spending On Buying Shares? – Yahoo Finance” on August 27, 2019, also Benzinga.com with their article: “Stocks That Hit 52-Week Lows On Thursday – Benzinga” published on September 12, 2019, Benzinga.com published: “The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen’s Blood Cancer Drug – Benzinga” on September 25, 2019. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: Benzinga.com and their article: “48 Stocks Moving In Monday’s Mid-Day Session – Benzinga” published on August 19, 2019 as well as Globenewswire.com‘s news article titled: “Myovant Sciences to Present at Upcoming June Investor Conferences – GlobeNewswire” with publication date: June 04, 2019.

https://financerecorder.com/analyst-at-cowen-co-reaffirmed-myovant-sciences-myovstock-rating-as-a-buy/